[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626601":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":68,"collaborators":24,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":24,"enrollmentInfo":81,"targetDuration":24,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":37,"whyStopped":24,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Grigore T. Popa University of Medicine and Pharmacy","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of care","ACTIVE_COMPARATOR","Takes into account the SCTs -PT\u002FINR, platelet count and serum fibrinogen levels to guide transfusion prior to high risk of bleeding invasive procedure. If INR ≤1.8, platelet count ≥50,000\u002Fmm3 and serum fibrinogen ≥120 mg\u002FdL, no transfusion is indicated. Otherwise, if INR \\>1.8, FFP is transfused at 10 mL per kg of body weight; and\u002For if platelet count \\\u003C50,000\u002Fmm3, 1 unit per 10 kg of body weight of platelets (up to 10 units) is transfused; and\u002For if serum fibrinogen \\\u003C120 mg\u002FdL, 1 unit per 10 kg of body weight of cryoprecipitate is transfused (up to 10 units).",[13],"Procedure: Blood Products transfusion",{"label":15,"type":16,"description":17,"interventionNames":18},"ROTEM-based","EXPERIMENTAL","The thromboelastometry-based transfusion protocol uses EXTEM and FIBTEM. No transfusion is necessary when CT-EXTEM is ≤80 s and A10-EXTEM is ≥40 mm. For patients in whom CT-EXTEM is \\>80 s, transfusion of 10 mL per kg of body weight of FFP will be performed. If the patient presents an A10-EXTEM \\\u003C40 mm, the investigators will further evaluate the A10-FIBTEM. If A10-FIBTEM is ≥10 mm (indicating adequate fibrinogen function), platelet units (1 unit per 10 kg of body weight; maximum 10 units) will be transfused. Otherwise, if A10-FIBTEM is \\\u003C10 mm (indicating fibrinogen deficiency), cryoprecipitate (1 unit per 10 kg of body weight; maximum 10 units) will be transfused.",[13],[20],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Blood Products transfusion",[15,9],null,[26],{"name":27,"affiliation":5,"role":28},"Irina Girleanu, Associated Professor","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":24,"email":33},"CONTACT","+40762278575","gilda_iri25@yahoo.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Institute of Gastroenterology and Hepatology","RECRUITING","Iași","Iaşi","700111","Romania","RO",{"type":44,"coordinates":45},"Point",[46,47],27.6,47.16667,{"lat":47,"lon":46},[50,54,55,57,60,62,64,66],{"name":51,"role":31,"phone":52,"phoneExt":24,"email":53},"Cristina Muzica, Lecturer, MD, PhD","+40747521793","lungu.chirstina@yahoo.com",{"name":24,"role":31,"phone":24,"phoneExt":24,"email":33},{"name":56,"role":28,"phone":24,"phoneExt":24,"email":24},"Irina Girleanu, Associated Professor, MD, PhD",{"name":58,"role":59,"phone":24,"phoneExt":24,"email":24},"Cristina Muzica, Lecturer, MD, Phd","SUB_INVESTIGATOR",{"name":61,"role":59,"phone":24,"phoneExt":24,"email":24},"Laura Huiban, Lecturer",{"name":63,"role":59,"phone":24,"phoneExt":24,"email":24},"Sebastian Zenovia, Teaching Assistant, MD, PhD",{"name":65,"role":59,"phone":24,"phoneExt":24,"email":24},"Iulian Buzincu, Teaching Assistant, MD, PhD",{"name":67,"role":59,"phone":24,"phoneExt":24,"email":24},"Raluca Avram, Teaching Assistant, MD",{"type":28,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Irina Girleanu","Associated Professor","100626601","thrombelastometry-guided-blood-component-administration-versus-standard-of-care-in-patients-with-decompensated-liver-cirrhosis-undergoing-invasive-procedures-100626601",false,"NCT07437755","Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing Invasive Procedures","Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing High Risk of Bleeding Invasive Procedures","PROTECT-CIRR","Inclusion Criteria:\n\n* diagnosed with decompensated liver cirrhosis of any etiology\n* planned for a high risk of bleeding invasive procedure\n* coagulopathic based on conventional coagulation tests and considered for pre-procedural blood component prophylaxis\n* able and willing to provide informed consent\n\nExclusion Criteria:\n\n* acute liver failure\n* current use of anticoagulant treatment\n* patients on antiplatelet aggregation agents\n* patients who have received FFP, platelet transfusion, cryoprecipitate in the week prior to the procedure\n* patients with stage 4 or 5 chronic kidney disease or patients receiving renal replacement therapy\n* sepsis","ALL","18 Years",{"count":82,"type":83},116,"ESTIMATED","INTERVENTIONAL",[86],"NA","Patients with liver cirrhosis have historically received prophylactic transfusions before invasive procedures with high risk of bleeding. The optimal method for establishing the need of blood transfusion before invasive procedures in cirrhotic patients has not been determined yet, and there are not enough scientific data to warrant empirical transfusion. In many surgical and trauma-related contexts, viscoelastic tests, like Rotational Thromboelastometry (ROTEM), offer a comprehensive assessment of hemostasis, and it has been demonstrated to predict bleeding risk more accurately than traditional coagulation tests. The aim of this project is to evaluate the efficacy of a ROTEM-based algorithm in managing the administration of prophylactic blood components to patients diagnosed with decompensated liver cirrhosis undergoing invasive high risk of bleeding procedures. The investigators hypothesized that ROTEM-based decision-making will lead to a reduction in pre-procedural blood component usage, particularly fresh frozen plasma (FFP), compared with standard of care, whilst maintaining optimal clinical outcomes. The investigators will perform a prospective, single-center, randomized controlled clinical trial in a tertiary university hospital in Romania, comparing ROTEM-guided prophylactic blood component administration to standard of care in patients with decompensated cirrhosis and coagulopathy undergoing invasive procedures. Inclusion criteria: adults (aged 18 years or older) admitted with cirrhosis and an indication for high risk of bleeding invasive procedure defined as: transjugular liver biopsy, transjugular intrahepatic portosystemic shunt, endoscopic retrograde cholangio-pancreatography with sphincterotomy, endoscopic polypectomy of polyps more than 1 cm, variceal banding and complex dental extraction. The primary safety endpoint will be the incidence of major bleeding. Secondary endpoints will be the proportion of blood products transfusion, hospital length of stay, in-hospital and 28-day mortality, incidence of minor bleeding, transfusion related adverse reactions, and cost analysis.",[89],"Liver Cirrhosis With Acute Decompensation",[91,92,93,94],"ROTEM","decompensated liver cirrhosis","bleeding risk","blood product transfusion","2026-02-24",{"date":97,"type":98},"2026-02-27","ACTUAL",{"date":100,"type":98},"2025-06-01",{"date":102,"type":83},"2026-10-31",{"name":5,"class":6},1]